The first vaccine against dengue fever, from France’s Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world’s fastest-growing tropical disease. The late-stage trial involved 10,275 healthy children aged 2-14 across five countries in Asia, a region that accounts for over two-thirds of the mosquito-borne disease’s global burden. Sanofi had already disclosed in April that its vaccine reduced the incidence of dengue fever by 56 percent in the Asian study, without giving details. The full findings were published online on Friday in The Lancet medical journal. The study found the vaccine was safe and reduced the most serious cases of haemorrhagic fever by nearly 90 percent. But it offered poor protection to young children – who are most at risk from dengue – and proved notably inefficient in tackling one of the viral disease’s four strains. The results suggest the new vaccine acts best as an immune booster for patients with some previous exposure, and therefore may be most useful in tropical regions where dengue is common, rather than as a vaccination for travellers. Since there is no vaccine now, that could still make it an important weapon…
- WHO, New international advice on the dengue vaccine
- Top agenda: Vaccines, EJK and rice for the poor
- Commission could play greater role in harmonising vaccines supply, industry says
- Phipps officially opens vaccination week observances
- Good Morning Britain condemned for spreading anti-vaccination myths with 'offensive' canine autism debate
- We need to remind ourselves that vaccines save lives
- The 3 Questions Mark Zuckerberg Hasn’t Answered
- More than 200 MPs call for Windrush promises to become law
- Will Cal Jet deliver on promised Carlsbad flights to Bay Area, Phoenix?
- Why philosophy is taking its time to answer the big questions – J L Schellenberg
Sanofi dengue vaccine promising but questions remain have 290 words, post on at July 11, 2014. This is cached page on IT Breaking News. If you want remove this page, please contact us.